Literature DB >> 21721047

Molecular dynamics study of small molecule inhibitors of the Bcl-2 family.

Stéphane Acoca1, Qizhi Cui, Gordon C Shore, Enrico O Purisima.   

Abstract

We carried out docking and molecular dynamics simulations on ABT-737 and obatoclax, which are inhibitors of the Bcl-2 family of proteins. We modeled the binding mode of ABT-737 with Bcl-x(L) , Bcl-2, and Mcl-1 and examined their dynamical behavior. We found that the binding of the chlorobiphenyl end of ABT-737 was quite stable across all three proteins. However, the phenylpiperazine linker group was dramatically more mobile in Mcl-1 compared to either Bcl-x(L) or Bcl-2. The S-phenyl group at the p4 binding site was well-anchored in Bcl-x(L) and Bcl-2 but was somewhat more mobile in Mcl-1 although the phenyl ring itself on average stayed close to the p4 binding site in Mcl-1. This greater mobility is likely due to the greater openness of the p3 and p4 binding sites on Mcl-1. The calculated binding free energies were consistent with the much weaker binding affinity of ABT-737 for Mcl-1. Obatoclax was predicted to bind at the p1 and p2 binding sites of Mcl-1 and the binding mode was quite stable during the molecular dynamics simulation with Mcl-1 wrapping around the molecule. The modeled binding mode suggests that obatoclax is able to inhibit all three proteins because it makes use of the p1 and p2 binding sites alone, which is a fairly narrow groove in all three proteins unlike the p4 binding site, which is much broader in Mcl-1.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21721047     DOI: 10.1002/prot.23083

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  10 in total

1.  Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.

Authors:  Kenichiro Doi; Rongshi Li; Shen-Shu Sung; Hongwei Wu; Yan Liu; Wanda Manieri; Gowdahalli Krishnegowda; Andy Awwad; Alden Dewey; Xin Liu; Shantu Amin; Chunwei Cheng; Yong Qin; Ernst Schonbrunn; Gary Daughdrill; Thomas P Loughran; Said Sebti; Hong-Gang Wang
Journal:  J Biol Chem       Date:  2012-02-06       Impact factor: 5.157

2.  Modular access to complex prodiginines: total synthesis of (+)-roseophilin via its 2-azafulvene prototropisomer.

Authors:  James H Frederich; Patrick G Harran
Journal:  J Am Chem Soc       Date:  2013-03-01       Impact factor: 15.419

Review 3.  Targeting MCL-1 in hematologic malignancies: Rationale and progress.

Authors:  Andrew H Wei; Andrew W Roberts; Andrew Spencer; Aaron Seth Rosenberg; David Siegel; Roland B Walter; Sean Caenepeel; Paul Hughes; Zach McIver; Khalid Mezzi; Phuong Khanh Morrow; Anthony Stein
Journal:  Blood Rev       Date:  2020-02-21       Impact factor: 8.250

4.  Identification of a Covalent Molecular Inhibitor of Anti-apoptotic BFL-1 by Disulfide Tethering.

Authors:  Edward P Harvey; Zachary J Hauseman; Daniel T Cohen; T Justin Rettenmaier; Susan Lee; Annissa J Huhn; Thomas E Wales; Hyuk-Soo Seo; James Luccarelli; Catherine E Newman; Rachel M Guerra; Gregory H Bird; Sirano Dhe-Paganon; John R Engen; James A Wells; Loren D Walensky
Journal:  Cell Chem Biol       Date:  2020-05-14       Impact factor: 8.116

5.  Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.

Authors:  David J Richard; Ryan Lena; Thomas Bannister; Noel Blake; William E Pierceall; Nicole E Carlson; Christina Eberhart Keller; Marcel Koenig; Yuanjun He; Dmitriy Minond; Jitendra Mishra; Michael Cameron; Timothy Spicer; Peter Hodder; Michael H Cardone
Journal:  Bioorg Med Chem       Date:  2013-08-15       Impact factor: 3.641

Review 6.  Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1.

Authors:  Andrew M Beekman; Lesley A Howell
Journal:  ChemMedChem       Date:  2015-12-23       Impact factor: 3.466

7.  TREX1 as a Novel Immunotherapeutic Target.

Authors:  Wayne O Hemphill; Sean R Simpson; Mingyong Liu; Freddie R Salsbury; Thomas Hollis; Jason M Grayson; Fred W Perrino
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

8.  Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members.

Authors:  Ali Hosseini; Margarita Espona-Fiedler; Vanessa Soto-Cerrato; Roberto Quesada; Ricardo Pérez-Tomás; Victor Guallar
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

9.  Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.

Authors:  Mai Nguyen; Regina Cencic; Franziska Ertel; Cynthia Bernier; Jerry Pelletier; Anne Roulston; John R Silvius; Gordon C Shore
Journal:  BMC Cancer       Date:  2015-08-01       Impact factor: 4.430

10.  Estrogen regulation of anti-apoptotic Bcl-2 family member Mcl-1 expression in breast cancer cells.

Authors:  Jennifer L Schacter; Elizabeth S Henson; Spencer B Gibson
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.